Rheumatoid Arthritis: Beyond TNF Inhibitors, 2026 Dublin,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
41
Rheumatoid Arthritis: Beyond TNF Inhibitors, 2026

Dublin, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026" report to their offering. The Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026 report provides a comprehensive analysis of the current market landscape of rheumatoid arthritis based therapies (specifically, non - tumor necrosis factor (TNF) inhibitors) and an informed opinion on how the market is likely to evolve over the next decade. RA is known to substantially affect patients' quality of life and is characterized by a more severe set of symptoms than those observed in patients with osteoarthritis. The RA market is primarily populated by DMARDs that have been shown to alter the course of the disease and also improve radiographic outcomes. Biologic DMARDs including TNF inhibitors, such as HUMIRA® (USD 14 billion) , Enbrel® (USD 9 billion) , and REMICADE® (USD 6.6 billion) , are counted among the best-selling drugs in this market. In recent years, treatment options for RA have increased substantially with the development of several novel drugs/drug classes. In addition to TNF inhibitors, a number of novel biologic DMARDs, such as T-cell costimulatory blocking agents (Orencia®), B-cell depleting agents (Rituxan®), interleukin-6 (IL-6) inhibitors (Actemra®) and interleukin-1 (IL-1) receptor antagonists (Kineret®), have been approved over the past few years. In 2012, Xeljanz®, the first oral non-biologic DMARD belonging to the janus kinase (JAK) inhibitors drug class was approved in the US. The drug generated revenues worth USD 523 million in 2015 alone. In comparison to traditional biologic DMARDs, which are delivered through injections or infusions, JAK inhibitors, or Jakinibs, are a new class of drugs that have been optimized for oral delivery. It is also worth mentioning that a number of pharmaceutical companies are developing drugs with novel mechanisms of action, namely Bruton's tyrosine kinase (BTK) inhibitors, spleen tyrosine kinase (SYK) inhibitors, RANKL inhibitors and adenosine A3 receptor (A3AR) agonists, which (along with Jakinibs) represent the next generation of drugs designed to treat RA. During the course of our study, we identified over 80 non-TNF inhibitors that are either already marketed or in various phases of development for the treatment of RA; of these, five drugs are currently marketed and four drugs (a JAK inhibitor, a RANKL inhibitor and two IL-6R inhibitors) are in the pre-registration stage. Overall, more than 60% of candidate drugs are currently under clinical development. Drug development efforts in this domain are being actively led by a mix of pharmaceutical giants, mid-sized companies and start-ups. Among other things, the report features discussions on: - The current state of the market with respect to available drug classes, key players, phase of development of pipeline products (clinical and preclinical/discovery), route of administration, type of molecule and type of therapy. - An in-depth analysis comprising of schematic representations, including a grid analysis highlighting the distribution of pipeline, an overview of the landscape of industrial developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of RA therapeutics. - Detailed profiles of drugs that have been recently (post-2010) approved/marketed or are in the late stages of development (phase III and above). - Information on the mechanisms of action of novel drugs (non-TNF inhibitor) that are currently being investigated as potential treatment options for RA. - Detailed comparative analysis of the key clinical trial endpoints for drugs that are already marketed or are in phase III of development and insights on the clinical development programs designed for phase III drugs (active comparator trials, important primary endpoints and scale of trials). - A detailed analysis of the collaborations and agreements established amongst stakeholders in the past few years. - Emerging trends and a discussion on the popularity of non-TNF inhibitors on Twitter over the last few years. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Novel Drugs to Treat Rheumatoid Arthritis: Key Mechanisms of Action 6. JAK Inhibitors 7. Interleukin-6 Inhibitors 8. Novel Drugs for Rheumatoid Arthritis 9. Market Forecast 10. Key Insights 11. Recent Collaborations 12. Emerging Trends on Social Media 13. Conclusion 14. Appendix 1: Tabulated Data 15. Appendix 2: List of Companies and Organizations - AB Science - AbbVie - Abbott Laboratories - Acetylon Pharmaceuticals - Aclaris Therapeutics - Adverum Biotechnologies - Aegera Therapeutics - Alder BioPharmaceuticals - Allergan - Almac Group - Amgen - Antitope - ArGentis Pharmaceuticals - Arrien Pharmaceuticals - Arthrogen - Asahi Kasei Pharma Corporation - Asana BioSciences - Astellas Pharma - AstraZeneca - Atlantic Bio Sci - Avexxin - Bayer HealthCare - BeiGene - Biogen Idec - Bird Rock Bio - Boehringer Ingelheim - Bristol-Myers Squibb - CASI Pharmaceuticals - CJ HealthCare - CMC Biologics - CONBA Pharmaceuticals - CSL - Can-Fite BioPharma - Centocor - ChemoCentryx - Chugai Pharmaceuticals - Cipher Pharmaceuticals - CleveXel Pharma - Commence Bio - Cyclacel - Daiichi Sankyo - Dendright Technology - Dynamix Pharmaceuticals - Eli Lilly - Eternity Bioscience - Evotec - Five Prime Therapeutics - Galapagos - Genentech - Genor BioPharma - Genosco - Gilead Sciences - GlaxoSmithKline - Glenmark Pharmaceuticals - Hanmi Pharmaceutical - HitGen - Hubei Bio Pharmaceutical Industry Technology Institute - Human Genome Sciences - Hutchison Medi Pharma - Iltoo Pharma - Immune Response Biopharma - Immunex - ImmusanT - Incyte Corporation - Innate Pharma - Intarcia Therapeutics - Janssen - Jiangsu Hengrui Medicine - KBP BioSciences - Kangstem Biotech - Kwangdong Pharmaceutical - Levolta Pharmaceuticals - Lexicon Pharmaceuticals - MacroGenics - MedImmune - Merck Serono - Mesoblast - Molecular Partners - MorphoSys - Morphotek - NapaJen Pharma - NovImmune - Novartis - Numab - Ono Pharmaceutical - Ortho Biotech - Oscotec - Peptinov - Pfizer - Philogen - Pivotal BioSciences - Portola Pharmaceuticals - Principia Biopharma - Protalex - RedHill Biopharma - Redx Pharma - Regeneron Pharmaceuticals - Rigel Pharmaceuticals - Roche - Rottapharm Biotech - SBI Biotech - Sanofi-Aventis - Seikagaku Corporation - Sevion Therapeutics - Shanghai Institute of Materia Medica - Sorrento Therapeutics - Sun Pharma - Sunesis Pharmaceuticals - Taiho Pharmaceutical - Takeda Pharmaceuticals - TechnoPhage - The Veterans Affairs Medical Center of Memphis - TiGenix - Toleranzia - Translational Biosciences - UCB - University of Melbourne - University of Tennessee Health Science Center - Vitae Pharmaceuticals - Vitaeris - WuXi AppTec - Xencor - Yungjin Pharmaceutical - Ziarco Pharma For more information about this report visit http://www.researchandmarkets.com/research/kcdqt3/rheumatoid

About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Immune Disorders Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 158

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 13

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 49

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 118

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump's Tariff Threats Spark Global Market Reactions

Updated Category News Views 163

Market Reactions to Tariff Developments As global markets navigate uncertain waters today, optimism and anxiety intertwine. The US dollar has taken a slight step higher, while gold has seen a dip, all stemming from ongoing trade tensions and recent tariff announcements by President Trump. With negotiations that are seen as promising but fraught with complexities, the...

Continue Reading
Sutro Biopharma's Upcoming Presentation at J.P. Morgan Event

Updated Category News Views 228

Sutro Biopharma's Upcoming Conference Presentation Sutro Biopharma, Inc. (NASDAQ: STRO), a trailblazer in oncology therapies based in South San Francisco, has some exciting news. The company announced that its Chief Executive Officer, Bill Newell, will be presenting at the prestigious J.P. Morgan Healthcare Conference. This annual event is a pivotal opportunity for...

Continue Reading
Nightly Launches Ambitious $25 Million Experience Initiative

Updated Category News Views 302

Nightly Introduces a $25 Million Initiative In a bold move to reshape the live entertainment landscape, Nightly has announced a substantial $25 million initiative aimed at expanding its dynamic experiences across the nation. Originating from Dallas, Nightly has quickly evolved into a cultural movement that seeks to redefine nightlife specifically for Gen Z audiences. This...

Continue Reading
Tecan Announces 2024 Results, Focuses on Growth and Innovation

Updated Category News Views 609

Tecan Reports 2024 Financial Results Amid Market Challenges Overview of Financial Highlights Tecan has unveiled its financial results for 2024, showcasing a robust commitment to enhancing operational resilience in a challenging market environment. Sales figures totaled CHF 934.3 million, marking a decline from the previous year's CHF 1,074.4 million. This 13.0% drop in...

Continue Reading
Auddia, Inc. (AUUD) Merger: Shareholder Alert and Investigation Insights

Updated Category News Views 227

Auddia, Inc. (NASDAQ: AUUD) is under the microscope after news broke about its proposed merger with McCarthy Finney, Inc., which sent shockwaves through trader desks and shareholder circles alike. The date was February 18, 2026, when class action attorney Juan Monteverde announced an investigation into the deal that’s left many scratching their heads about whether this...

Continue Reading